| Literature DB >> 26108872 |
Maryam Zahedifard1, Fadhil Lafta Faraj2, Mohammadjavad Paydar3, Chung Yeng Looi3, Maryam Hajrezaei1, Mohadeseh Hasanpourghadi3, Behnam Kamalidehghan3, Nazia Abdul Majid1, Hapipah Mohd Ali2, Mahmood Ameen Abdulla4.
Abstract
The current study investigated the cytotoxic effect of 3-(5-chloro-2-hydroxybenzylideneamino)-2-(5-chloro-2-hydroxyphenyl)-2,3-dihydroquinazolin-41(H)-one (A) and 3-(5-nitro-2-hydroxybenzylideneamino)-2-(5-nitro-2-hydroxyphenyl)-2,3-dihydroquinazolin-4(1H)-one (B) onEntities:
Mesh:
Substances:
Year: 2015 PMID: 26108872 PMCID: PMC4479988 DOI: 10.1038/srep11544
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 11H NMR spectrum of compound (A) in (400 MHz, DMSO-d6).
Figure 21H NMR spectrum of a compound (B) in (400 MHz, DMSO-d6).
Figure 313C NMR spectrum of the compounds (A and B ) in (100 MHz, DMSO-d6).
Figure 4Crystal structure of compound (B).
X-ray crystallographic data table for compound (B).
| Identification code | Compound (B) |
|---|---|
| C23H18N6O7 | |
| 490.43 | |
| 296(2) | |
| monoclinic | |
| P21/n | |
| 10.757(2) | |
| 15.543(4) | |
| 14.063(3) | |
| 90.00 | |
| 92.781(4) | |
| 90.00 | |
| 2348.5(9) | |
| 4 | |
| 1.387 | |
| 0.106 | |
| 1016.0 | |
| 0.17 × 0.13 × 0.09 | |
| MoKα (λ = 0.71073) | |
| 4.6 to 52.78 | |
| −13 ≤ h ≤ 11, −17 ≤ k ≤ 19, −15 ≤ l ≤ 17 | |
| 12436 | |
| 4763 [Rint = 0.0271, Rsigma = 0.0349] | |
| 4763/6/338 | |
| 1.008 | |
| R1 = 0.0435, wR2 = 0.1106 | |
| R1 = 0.0791, wR2 = 0.1315 | |
| 0.17/−0.15 |
Crystal Data for compound (B) C23H18N6O7 (M =490.43 g/mol): monoclinic, space group P21/n (no. 14), a = 10.757(2) Å, b = 15.543 (4) Å, c = 14.063 (3) Å, β = 92.781 (4)°, V = 2348.5 (9) Å3, Z = 4, T = 296 (2) K, μ(MoKα) = 0.106 mm-1, Dcalc = 1.387 g/cm3, 12436 reflections measured (4.6° ≤ 2Θ ≤ 52.78°), 4763 unique (Rint = 0.0271, Rsigma = 0.0349) which were used in all calculations. The final R1 was 0.0435 (>2sigma(I)) and the wR2 was 0.1315 (all data).
IC50 values of compounds against MCF-7, MCF-10A and WRL68 cell lines.
| Compound | Cell line | Classification | IC50 (μg/ml) | ||
|---|---|---|---|---|---|
| MCF-7 MDA-MB-231 | Breast cancer cells | 7.42 ± 0.423 50< | 3.76 ± 0.251 50< | 3.27 ± 0.171 50< | |
| MCF-10A WRL-68 | Normal breast cells Normal hepatic cells | 25< 40< | 25< 40 < | 25< 40< | |
| MCF-7 MDA-MB-231 | Breast cancer cells | 10.67 ± 0.551 50< | 5.87 ± 0.401 50< | 4.36 ± 0.219 50< | |
| MCF-10A WRL-68 | Normal breast cells Normal hepatic cells | 25< 40< | 25< 40 < | 25< 40< | |
Figure 5Lactate dehydrogenase (LDH) assay.
The LDH release assay revealed significant cytotoxicity of quinazolinone-based compounds on MCF-7 cells at 4–8 μg/mL of compound A and at 6–12 μg/mL of compound B.
Figure 6Fluorescent micrographs of AO/PI-double-stained MCF-7 cells.
(A) Untreated MCF-7 cells exhibit normal structures. (B1) and (C1) Early apoptosis features, namely, blebbing and chromatin condensation as well as late apoptotic cells were detected after 24 hours of treatment with (A) and (B). (B2) and (C2) Late apoptosis and secondary necrosis were observed after 48 h treatment with (A) and (B), respectively (magnification: 200×). VI: Viable cells; CC: Chromatin condensation; BL: Blebbing of the cell membrane; LA: Late apoptosis; SN: Secondary necrosis.
Figure 7Effect of compound A and B on the generation of ROS.
(A) The level of ROS was significantly elevated at 4–8 μg/mL concentrations of compound A and (B) at 6–12 μg/mL concentrations of compound B.
Figure 8Effects of the Quinazoline Schiff bases on membrane permeability, mitochondrial membrane potential (MMP) and cytochrome c release.
(1) Representative images of MCF-7 cells treated with medium alone and compounds (A and B) at 4 and 6 μg/mL, respectively, and stained with Hoechst 33342 for nuclei, cytochrome c, membrane permeability and MMP dyes. Both compounds induced a noteworthy elevation in membrane permeability and cytochrome c release and a marked reduction in mitochondrial membrane potential (magnification: 200×). (2) Representative bar charts indicating dose-dependent increases in cell permeability, reduced MMP and increased cytochrome c release in A- and B-treated MCF-7 cells.
Figure 9(1) Relative luminescence time-dependent expression of caspases 3/7, -8 and -9.
MCF-7 cells treated with A and B at concentrations of 4 and 6 μg/mL, respectively, after 24 hours of incubation showed significant expression of caspases 3/7, -8 and -9. (2) Western blot analysis of A- and B-treated MCF-7 cells. Cells were treated with compounds for 24 hours before being lysed and subjected to separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Proteins were then transferred to a membrane and probed with antibodies against caspase 7, -9 and Bid. The membrane was reprobed with anti-β-actin antibody as the loading control. The band densities of treated samples were normalized to the control. The results revealed significant activation of caspases -7, -9 and Bid.
Figure 10NF-κB translocation.
(1) Photographs of the intracellular targets of stained MCF-7 cells that were exposed to A and B at concentrations of 4 and 6 μg/mL, respectively, for 3 hours and then stimulated for 30 minutes with 1 ng/ml TNF-α (NF-κB activation). (2) Representative bar chart showing translocation of TNF-α induced NF-kB in MCF-7 cells at different concentrations.
Effects of 250 mg/kg A and B on the renal function test.
| Groups | Sodium (mmo/L) | Potassium (mmol/L) | Chloride (mmol/L) | CO2(mmol/L) | Anion gap (mmol/L) | Urea (mmol/L) |
|---|---|---|---|---|---|---|
| 145 ± 0.91 | 8.7 ± 0.15 | 109.4 ± 0.32 | 20.5 ± 0.34 | 27.0 ± 0.6 | 6.5 ± 0.7 | |
| 148.3 ± 0.68 | 9.0 ± 0.12 | 108.5 ± 0.36 | 23.5 ± 0.78 | 25.9 ± 0.7 | 6.8 ± 0.4 | |
| 152.9 ± 0.66 | 8.2 ± 0.1 | 113.8 ± 0.38 | 18.2 ± 0.28 | 23.2 ± 0.4 | 7.9 ± 0.3 |
Values are expressed as the means ± S.E.M. There were no statistically significant differences between the measurements of different groups. Significance was set at P < 0.05.
Figure 11Histological sections in the acute toxicity test (H&E staining, 20x).
Histological sections of liver (first row) and kidney (second row). Untreated mice (control group) received 5 mL/kg vehicle (5% Tween 20) ((A) and (D)). Animals treated with 250 mg/kg are ((B) and (E)) and ((C) and (F)) for compounds A and B, respectively. There were no significant differences in the structures of the liver or kidneys between the treated and untreated group.
Figure 12The synthetic pathway of the compounds (A and B).
Figure 13The chemical structure of Compound (A).
Figure 14The chemical structure of Compound (B).
Effects of 250 mg/kg A and B on the liver function test.
| Groups | Total protein (g/L) | Albumin (g/L) | Globulin (g/L) | AP (IU/L) | ALT (IU/L) | AST (IU/L) | GGT (IU/L) |
|---|---|---|---|---|---|---|---|
| 52.0 ± 1.5 | 12.4 ± 0.65 | 51.4 ± 1.1 | 85.3 ± 3.2 | 58.9 ± 5.4 | 251 ± 8.4 | 3.5 ± 0.1 | |
| 52 ± 1.5 59 ± 1.0 | 10.5 ± 0.62 11.2 ± 0.43 | 51.3 ± 1.2 50.6 ± 1.4 | 88.6 ± 2.8 90.2 ± 3.1 | 62.2 ± 4.3 60.0 ± 4.4 | 265 ± 6.5 244 ± 5.9 | 3.1 ± 0.08 3.0 ± 0.05 |
Values are expressed as the means ± S.E.M. There were no statistically significant differences between the measurements of different groups. Significance was set at P < 0.05.